Highlights
ThromboGenics continues to advance its attractive portfolio of innovative medicines for the treatment of diabetic eye disease: 4 novel treatments for diabetic retinopathy (DR) - non-proliferative diabetic retinopathy (NPDR) and proliferative diabetic retinopathy (PDR), in the presence or absence of diabetic macular edema (DME)
Clinical Update
Phase II study: THR-409 (Ocriplasmin) for Non Proliferative Diabetic Retinopathy (CIRCLE)
? The Phase II study (CIRCLE) is assessing the ability of multiple doses of THR-409 to induce a total PVD in patients with NPDR.
? CIRCLE will also explore whether generating a total PVD in patients with non-proliferative diabetic retinopathy could prevent the disease from progressing to proliferative diabetic retinopathy, a serious sight threatening condition.
? In December, the CIRCLE study protocol was amended to allow inclusion of patients with less severe non-proliferative diabetic retinopathy. This change was made to broaden the patient pool for this study to recruit from.
For full access, please click here.
ThromboGenics continues to advance its attractive portfolio of innovative medicines for the treatment of diabetic eye disease: 4 novel treatments for diabetic retinopathy (DR) - non-proliferative diabetic retinopathy (NPDR) and proliferative diabetic retinopathy (PDR), in the presence or absence of diabetic macular edema (DME)
Clinical Update
Phase II study: THR-409 (Ocriplasmin) for Non Proliferative Diabetic Retinopathy (CIRCLE)
? The Phase II study (CIRCLE) is assessing the ability of multiple doses of THR-409 to induce a total PVD in patients with NPDR.
? CIRCLE will also explore whether generating a total PVD in patients with non-proliferative diabetic retinopathy could prevent the disease from progressing to proliferative diabetic retinopathy, a serious sight threatening condition.
? In December, the CIRCLE study protocol was amended to allow inclusion of patients with less severe non-proliferative diabetic retinopathy. This change was made to broaden the patient pool for this study to recruit from.
For full access, please click here.
